title: Microwave tumour coagulation plus in situ treatment with cytokine-microparticles: induction of potent anti-residual tumour immunity.
abstract: After local microwave coagulation and subsequent intra-tumoural injection of microparticles encapsulating interleukin-2 and granulocyte-macrophage colony-stimulating factor, the anti-tumour efficacy against subcutaneous Lewis lung carcinoma in syngeneic mice was evaluated. This treatment elicited a potent systemic anti-tumour immunity that protected treated mice from re-challenge with the same tumour cells and caused the distal tumours in a bilateral tumour model to be rejected. Cytotoxicity assay indicated that both T- and natural killer cells acted as the effector cells in the anti-tumour immunity. These data highlight the feasibility of microwave-pre-treated in situ cancer vaccination for clinical use.
authors: The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
authors: M
authors: M
authors: Kuang
authors: S Q
authors: SQ
authors: Liu
authors: K
authors: K
authors: Saijo
authors: E
authors: E
authors: Uchimura
authors: L
authors: L
authors: Huang
authors: K W
authors: KW
authors: Leong
authors: M D
authors: MD
authors: Lu
authors: J F
authors: JF
authors: Huang
authors: T
authors: T
authors: Ohno
mesh_terms: D000818:Animals; D017252:CD3 Complex / Q000276:immunology; D019496:Cancer Vaccines; D018827:Carcinoma, Lewis Lung / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D045744:Cell Line, Tumor; D004564:Electrocoagulation / Q000379:methods*; D005260:Female; D006084:Graft Rejection; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000494:pharmacology; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008863:Microspheres; D008872:Microwaves / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D047368:Tumor Burden
chemical_list: D017252:CD3 Complex; D019496:Cancer Vaccines; D007376:Interleukin-2; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor